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Abstract 
Synovial sarcoma is a relatively rare high-grade soft tissue sarcoma that often develops 
in the limbs of young people and induces the lung and the lymph node metastasis 
resulting in poor prognosis. In patients with synovial sarcoma, specific chromosomal 
translocation of t(X;18) (p11.2;q11.2) is observed, and SS18-SSX fusion protein 
expressed by this translocation is reported to be associated with pathogenesis. However, 
role of the fusion protein in the pathogenesis of synovial sarcoma has not yet been 
completely clarified. In this study, we focused on the localization patterns of SS18-SSX 
fusion protein. We constructed expression plasmids coding for the full length SS18-SSX, 
the truncated SS18 moiety (tSS18) and the truncated SSX moiety (tSSX) of SS18-SSX, 
tagged with fluorescent proteins. These plasmids were transfected in synovial sarcoma 
SYO-1 cells and we observed the expression of these proteins using a fluorescence 
microscope. The SS18-SSX fusion protein showed a characteristic speckle pattern in the 
nucleus. However, when SS18-SSX was co-expressed with tSSX, localization of 
SS18-SSX changed from speckle patterns to the diffused pattern similar to the 
localization pattern of tSSX and SSX. Furthermore, cell proliferation and colony 
formation of synovial sarcoma SYO-1 and YaFuSS cells were suppressed by exogenous 
tSSX expression. Our results suggest that the characteristic speckle localization pattern 
of SS18-SSX is strongly involved in the tumorigenesis through the SSX moiety of the 
SS18-SSX fusion protein. These findings could be applied to further understand the 
pathogenic mechanisms, and towards the development of molecular targeting approach 
for synovial sarcoma.   
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Introduction 
Synovial sarcoma is a relatively rare high-grade soft tissue sarcoma that often develops 
in the limbs of young people. Recent advancements in surgery, chemotherapy, 
radiotherapy, and multidisciplinary therapy have improved the prognosis. The overall 
5-year survival rate in synovial sarcoma patients without metastasis is reported to be 
61–80% [1-4]. However, in long-term, synovial sarcoma cells sometimes metastasize to 
the lung and the lymph node, turning into a life-threatening condition resulting in a poor 
prognosis. The pathogenic mechanisms have not yet been completely elucidated. 
However, specific chromosomal translocation of t(X;18) (p11.2;q11.2) has been 
identified in patients with synovial sarcoma [5]. The fusion of the SS18 gene on 
chromosome 18 to the SSX gene on chromosome X results in the expression of fusion 
protein SS18-SSX composed of the NH3-terminal half of the amino acids from SS18 
and COOH-terminal amino acids of the SSX. Expression of the fusion protein has been 
observed in more than 97% of synovial sarcoma cells [6-8]. This suggests that the 
SS18-SSX fusion protein is specifically expressed in the synovial sarcoma cells, and is 
important in the pathogenesis of the disease. SS18 and SSX proteins are localized in the 
nucleus and are associated with transcriptional regulation, although neither have a 
distinct DNA binding-domain [6-8]. Therefore, they are thought to regulate transcription 
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by interacting with other proteins that can bind directly to the DNA in the nucleus.  
The wild-type SS18 protein comprises 387 amino acid residues, being ubiquitously 
expressed in normal cells [6]. It has been reported that SS18 interacts with SNF/SWI 
complexes (a chromatin remodeling factor) [9-13], Sin3A (a factor of histone 
deacetylase complex) [14, 15], p300 [16], and AF10 [17]. SS18 is regarded as a 
transcriptional co-activator because it promotes transcription. 
Wild-type SSX protein consists of 188 amino acid residues [7], and it is expressed in the 
testis and the thyroid, along with melanoma and lung cancer tumor cells, and is one of 
the cancer/testis antigens [18-21]. Major fusion partners of SS18 in synovial sarcoma are 
SSX1 and SSX2, and SSX4 has been reported in rare cases [22, 23]. The SSX1 to SSX9 
genes have been identified [24]. SSX is reported to interact with transcriptional 
repressors such as the polycomb-group (PcG) [25-29], core histone [11], RAB3IP, and 
SSX2IP [27, 28, 30], and is regarded as a transcriptional co-repressor since it suppresses 
transcription. 
SS18-SSX fusion protein is also known to be localized in the nucleus [25, 26, 31, 32], 
and is reported to interact with a variety of proteins [10-12, 25, 26, 29, 33]. Recently, 
gene expression profiles using DNA microarray has revealed various downstream genes 
that are targeted by the SS18-SSX fusion protein [34-42]. The control of gene 
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expression by SS18-SSX is believed to involve chromatin remodeling, due to its 
colocalization with both Trithorax (TrxG) and Polycomb group (PcG) complexes, 
maintaining chromatin in a poised bivalent state [26, 39, 43]. Lubieniecka reported that 
EGR1 is repressed by the SS18-SSX protein through trimethylation of histone H3, and 
HDAC inhibitor reverts the histone modifications and reactivates EGR1 expression in 
synovial sarcoma cells [43]. Su et al identify ATF2 as the DNA-binding partner of 
SS18-SSX and showed that HDAC inhibitors reverse the epigenetic repressor activity of 
the SS18-SSX oncoprotein complex by preventing TLE1 recruitment. [44]. Several 
studies have demonstrated that synovial sarcoma cells express mRNA transcripts of 
pluripotency factors Sox2, Oct3/4, and Nanog [45] and harbor stem-cell-like gene 
expression profiles [46], and that tumor cells lacking the BAF47 tumor suppressor 
subunit express stem-cell-like signatures [47]. Kadoch and Crabtree demonstrated that 
SS18-SSX fusion protein binds to SWI/SNF-like BAF (chromatin-remodeling) 
complexes and evicts both the wild-type SS18 and the tumor suppressor BAF47. This 
altered complex binds to and activates the Sox2 locus by disrupting 
H3K27me3-mediated repression, and drives proliferation of these cells [48]. In 
transgenic mice, conditional overexpression of SS18-SSX2 in the myogenic progenitor 
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compartment, but not other compartments, leads to the appearance of both monophasic 
and biphasic synovial sarcoma tumors with full penetrance [49].  
Generally, proteins that function as transcriptional factors are believed to form 
complicated complexes, localize at specific region, and carry out their own functions. 
Synovial sarcoma cell line SYO-1 bearing the SS18-SSX2 translocation was established 
previously [50]. We investigated the localization pattern of each component of synovial 
sarcoma-related fusion protein, and examined the inhibiting effect of the localization of 
SS18-SSX protein in order to understand the mechanisms by which SS18-SSX 
contributes towards the synovial sarcoma pathogenesis.   
 
Results 
Localization patterns of synovial sarcoma-related proteins in the SYO-1 cells 
Localization of full-length SS18 and SSX proteins tagged to GFP was observed under 
fluorescence microscope, after the constructs pEGFP-SS18, pEGFP-SSX1, and 
pEGFP-SSX2 were transfected into SYO-1 cells. SS18 localized to the nucleus and 
showed a speckled distribution pattern (Fig. 1A). Both SSX1 and SSX2 localized in the 
nucleus and displayed a diffuse localization pattern. SSX1 also displayed a speckled 
pattern and the number of these speckles were relatively more in cells transfected with 
SSX1 than (Fig. 1B) compared to cells with SSX2 (Fig. 1C). Next, SS18-SSX fusion 
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proteins were observed after transfection of pEGFP-SS18-SSX1 and pEGFP-SS18-SSX2 
into SYO-1 cells. Both SS18-SSX1 and SS18-SSX2 were localized in the nucleus 
showing clear speckles similar to that observed for SS18. However, when we examined 
closely, compared to SS18, the fusion proteins displayed a pattern in which densely 
packed oval dots were more evenly distributed (Figs. 1G and 1H). There was no 
remarkable difference in the localization between SS18-SSX1 and SS18-SSX2. To 
examine the affect of the fluorescent protein on the localization, SS18, SSX2, and 
SS18-SSX2 proteins without GFP in transfected HEK293 cells were analyzed by 
fluorescence immunocytochemistry with anti-SS18 and anti-SSX antibodies. SS18 and 
SS18-SSX2 showed a speckled pattern and SSX2 displayed a diffuse pattern, which are 
similar to their localization of the proteins fused with GFP (Supplementary Fig. 1), 
suggesting that addition of the fusion protein doesn’t affect localization. Then, the 
GFP-fusion plasmids harboring SS18 moiety and SSX moiety were constructed. 
Localization of tSS18 (truncated SS18 composing of 1-379 amino acids), tSSX1, and 
tSSX2 (truncated SSX composing of 111-188 amino acids) was observed after 
transfection of pEGFP-tSS18, pEGFP-tSSX1 and pEGFP-tSSX2 into SYO-1 cells. The 
tSS18 showed a similar localization pattern in the nucleus as that of SS18, although the 
intensity of the fluorescence was weak (Fig. 1D). Localization pattern of tSSX1 and 
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tSSX2 did not differ remarkably from those of SSX1 and SSX2, respectively (Fig. 1E 
and F). We also looked at the localization patterns of these synovial sarcoma-related 
proteins in HEK293 cells transfected with these plasmids, the localization patterns were 
similar to that observed in SYO-1 cells (Supplementary Fig. 2). We confirmed that the 
proteins from these plasmid constructs were successfully expressed in HEK293 cells, by 
Western blotting with anti-SS18 and anti-SSX antibodies (Supplementary Fig. 3). 
 
Change in the localization pattern of SS18-SSX upon co-expression with truncated 
SS18 and SSX proteins 
Effect of tSS18 and tSSX truncated proteins on localization of SS18-SSX was examined 
in synovial sarcoma cells. When GFP-tagged SS18-SSX2 was co-transfected along with 
DsRedmonomer-tSS18 into SYO-1 cells, the localization pattern of SS18-SSX2 was not 
remarkably different from that observed in cells that were transfected with SS18-SSX2 
alone, but the localization of tSS18 was similar with that of SS18-SSX2 (Fig. 2, A1, and 
A2). We then looked at the changes in the localization pattern if any of the GFP-tagged 
SS18-SSX2 when co-expressed with DsRedmonomer-tSSX2 fusion in SYO-1 cells. The 
localization of SS18-SSX2 significantly changed from a speckled pattern to a diffuse 
localization pattern, and was similar to that of tSSX2 (Fig. 2, B1, and B2). When 
GFP-tagged SS18-SSX2 and DsRedmonomer-tSSX1 fusion were co-expressed, 
9 
 
localization of SS18-SSX2 also changed from speckled to a diffuse pattern, and was 
similar to that of tSSX1 (data not shown). When SS18-SSX1 was co-expressed with 
tSSX1, the localization of SS18-SSX1 also showed to a diffuse pattern (Supplementary 
Fig. 4). However, when pEGFP-SS18-SSX2 and pDsRedmonomer empty vector were 
co-expressed, localization of SS18-SSX2 did not change (Fig. 2, C1, and C2). When we 
transfected SYO-1 cells with DsRedmonomer-fused SS18, SSX1 and SSX2 full-length 
genes instead of using the truncated genes, the localization of SS18-SSX was similar to 
the localization pattern observed earlier (data not shown). We obtained similar results 
for the localization of these fusion proteins in HEK293 cells transfected with the above 
plasmids (Supplementary Figs. 5 and 6). All the cells showing a diffuse pattern we 
examined were observed to have red-fluorescence of tSSX2 in their nuclei. Therefore, 
we analyzed quantitatively the effect of increasing expression of tSSX on localization of 
SS18-SSX. Transfection of increased amount of DsRedmonomer-tSSX2 plasmid (0, 2, 4, 
and 6 µg) showed significant loss of cells with speckled pattern, while transfection of 
increased amount of DsRedmonomer-tSS18 plasmid never showed loss (Fig. 3). We 
examined effect of DsRedmonomer-tSSX2 and -tSS18 on GFP-SS18-SSX2 expression 
in transfected HEK293 cells by Western blotting analysis. However, the result showed 
that protein expression of SS18-SSX2 was not affected by that of tSSX2 and tSS18 
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(Supplementary Fig. 7). 
 
Suppression of cell proliferation of SYO-1 cells by exogenous expression of tSSX2 
As described above, the localization of SS18-SSX2 was affected by the co-expression 
of tSSX2 in SYO-1 cells. Therefore, we examined the effect of expression of tSSX2 on 
proliferation of SYO-1 cells harboring the SS18-SSX2 fusion gene. SYO-1 cells were 
transfected with GFP-fused tSSX2 or GFP vector alone as control, split 48 h after 
transfection, and the cells expressing the fluorescence proteins were observed and 
counted on day 4, 6, and 8 after transfection. The cell proliferation ratio was normalized 
by dividing the numbers of GFP expressing cells on days 6 and 8 by the number on day 
4 in SYO-1 cells transfected with tSSX2 and control group. The cell proliferation was 
significantly suppressed in the tSSX2 group on days 6 and 8 (Fig. 4). A time-course 
experiment showing the change in the number of GFP expressing cells is shown in Fig. 
5.   
 
Suppression of colony formation of synovial sarcoma cells by exogenous expression 
of tSSX 
 We examined the effect of tSSX2 expression on colony formation of SYO-1 cell line. 
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SYO-1 cells were transfected with GFP-tagged tSSX2 or GFP vector alone, split 48 h 
after transfection, and selected with G418 for three weeks. The colonies were observed 
after cell fixation and staining. The number of colonies formed as well as the size of the 
colony was decreased in the tSSX2 group as compared with that of the control group 
(Fig. 6A). We also studied the colony forming ability of another synovial sarcoma cell 
line YaFuSS harboring the SS18-SSX1 fusion gene. Reduced number of colonies was 
observed in YaFuSS cell line transfected with GFP-tagged tSSX1 (Fig. 6B).  
 
Discussion  
In the present study, the wild-type SS18 clearly showed a speckled localization pattern, 
while SSX showed primarily a diffuse pattern. The localization pattern of SS18-SSX 
fusion proteins was clearly nuclear with a speckled pattern and clear elliptical dots were 
densely distributed, which differed from those of the wild-type SS18 and SSX. In 
addition, localization of tSS18 and tSSX, which are components of SS18-SSX fusion 
protein did not remarkably differ from that of the wild-type SS18 and SSX, respectively. 
Hence, the localization pattern of SS18-SSX is thought to be the distinct feature 
obtained only when both SS18 and SSX form a fusion protein. The subtle difference of 
tSSX1 and tSSX2 localization is considered to depend on 11 different amino acids 
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between them. 
Several investigators have reported regarding the localization of synovial 
sarcoma-associated proteins. dos Santos et al. have reported that the SS18 displays a 
nuclear punctated localization pattern and SSX a diffuse pattern in the nucleus of 
transfected COS-1 cells [31]. They suggested that SS18 might influence the 
manifestation of the tumor since the SS18-SSX fusion protein is also localized in the 
nucleus and displays a similar punctated pattern [31]. Brett et al. also reported that SS18 
and SSX1 displayed a speckled and uniform distribution pattern in the nucleus, 
respectively, and that the localization pattern of SS18-SSX2 fusion protein is similar to 
that of SS18 in transfected NIH3T3, Cos-7, HT1080, and MRC-5 cells [32]. On the 
other hand, Soulez et al. reported that the co-localization of SS18-SSX fusion protein 
and SSX with RING1 and BMI1, which belong to polycomb group (PcG), but not SS18 
[26]. dos Santos et al. subsequently reported that HeLa and COS-1 cells harboring the 
SSX expression vector displayed speckles in the diffuse distribution, and the localization 
of speckles of SS18-SSX coincided with that of SSX [25]. Furthermore, when the 
C-terminus of the SSX region called the SSX repression domain was removed, the 
localization of SS18-SSX coincided with that of SS18 [26, 51]. Therefore, they 
concluded that SSX region played a dominant role over SS18 region in localization of 
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SS18-SSX and that the C-terminus of SSX was especially important [25].  
In our study, we demonstrate that the localization pattern of SS18-SSX changes 
significantly when co-expressed with tSSX, suggesting that the localization of 
SS18-SSX can be antagonized at least by tSSX. These results indicate that SS18-SSX 
might bind to other proteins via its SSX region; this agrees well with the results of 
Soulez et al. and dos Santos et al.[25, 26]. As the localization of SS18-SSX changed to a 
diffuse pattern upon co-expression of tSSX and this seems to coincide with the 
localization pattern of SSX and tSSX, the localization of SS18-SSX might be guided 
through the SSX region of SS18-SSX. Interestingly, since co-expression of tSSX2 
suppressed cell proliferation and colony formation of the synovial sarcoma SYO-1 and 
YaFuSS cell lines, the speckle distribution pattern characterized by SS18-SSX might be 
strongly involved in tumorigenesis of synovial sarcoma cells. Recently, Kadoch and 
Crabtree demonstrated that SS18-SSX protein binds to SWI/SNF-like BAF 
(chromatin-remodeling) complexes, and SS18-SSX-driven altered BAF complex 
formation depends on two amino acids of SSX [48]. Our results showing disappear of 
SS18-SSX speckles by exogenous tSSX transfection do not contradict their results, and 
the phenomenon we found might show the disruption of SS18-SSX-driven altered BAF 
complex antagonized by tSSX. The effect of tSSX on SS18-SSX speckle disruption 
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might depend on two amino acids of SSX at position 43 and 44. They still demonstrated 
that assembly of wild-type complexes and proliferative quiescence can be achieved by 
increasing the concentration of wild-type SS18. However, we haven’t performed a cell 
growth assay using tSS18 transfection, because we could not find any change of 
SS18-SSX localization by tSS18 transfection due to similarity of localization of 
SS18-SSX and tSS18. Our finding that tSS18 and SS18 co-localize with SS18-SSX 
spatially in nuclear might explain their results that increased expression of SS18 
displaces SS18-SSX from SWI/SNF-like BAF complexes and lead to reduced growth. 
Perani et al. reported that SS18 forms an oligomer with SS18 itself or with SS18-SSX 
[9]. If SS18-SSX forms an oligomer with tSS18, it could account for the same 
localization pattern observed for SS18-SSX and tSS18.  
SSX1 and SSX2 interact with BMI1 and RING1A, which belong to PcG and with 
LHX4, RAB3IP, and SSX2IP which are transcription factors [27, 28]. RAB3IP and 
SSX2IP interact with the N-terminal domain of SSX [27, 30]. Since SS18-SSX fusion 
proteins do not consist of the interaction domains, RAB3IP and SSX2IP are quite 
unlikely to be the candidate proteins interacting with SS18-SSX. Our results using SSX 
were similar between the two subtypes of SSX, and it is known that PcGs such as BMI1 
and RING1A interact with SSX1 and SSX2 commonly. Therefore, BMI1 and RING1A 
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could be the candidate proteins interacting with the SSX1 or SSX2 region of SS18-SSX 
fusion protein.  
Our results revealed the possibility that SS18-SSX is involved in tumor proliferation 
because of its interaction with some specific proteins interacting with the wild-type SSX 
via the SSX region of SS18-SSX. Further study is needed to identify these interacting 
proteins, which will provide a better understanding on the pathways involved in the 
pathogenesis of synovial sarcoma. This could provide new target molecules that could 
help in the development of newer treatment options for synovial sarcoma using 
molecular targeting approach.  
  
Materials and methods 
Cell lines 
Human synovial sarcoma cell line SYO-1 expressing the SS18-SSX2 fusion gene was 
established in our laboratory [50]. Human synovial sarcoma cell line YaFuSS expressing 
the SS18-SSX1 fusion gene was kindly provided by Dr. J. Toguchida (Institute for 
Frontier Medical Sciences, Kyoto University, Japan) [52]. Human normal embryonic 
kidney cell line HEK293 was purchased from American Type Culture Collection. These 
cell lines were grown in Dulbecco’s modified Eagle’s medium or RPMI-1640 
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(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum 
(Invitrogen), 100 units/ml of penicillin G and 100 µg/ml of streptomycin (Meiji Seika, 
Tokyo, Japan). All cells were incubated at 37oC in a humidified atmosphere containing 
5% CO2.  
  
Plasmid construction 
The coding regions of the human SS18-SSX1, SS18-SSX2, SS18, SSX1, SSX2, tSS18 
(truncated SS18 coding #1-379 amino acids), tSSX1 and tSSX2 (truncated SSX coding 
#111-188 amino acids) were amplified by PCR with cDNA derived from synovial 
sarcoma cells as described earlier [14]. The amplified cDNAs were inserted downstream 
of green fluorescent protein (GFP) of pEGFP-C vector (Clontech), and the expression 
plasmids were constructed to produce GFP tagged-SS18-SSX1, -SS18-SSX2, -SS18, 
-SSX1, -SSX2, -tSS18, -tSSX1 and -tSSX2 proteins. Furthermore, pDsRedmonomer 
plasmids bearing the SS18, SSX1, SSX2, tSS18, tSSX1 and tSSX2 cDNAs were inserted 
downstream of DsRedmonomer, to produce DsRedmonomer fusion proteins. To detect 
the localization of SS18, SSX2, and SS18-SSX2 by fluorescence immunocytochemistry, 
pCMV-Tag2B expression plasmids with FLAG tag containing these cDNAs were used 
for transfection as described [53] 
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Transfection 
To increase the transfection efficiency, reverse transfection method was used. The 
vectors (total DNA amount of 0.25 µg in cases where one kind of vector was used, and 
0.125 µg each in case of two kinds of vectors) were mixed with 1 µL of Effectene 
(QIAGEN), 3.25 µL EC-buffer, 1 µL enhancer and 0.6 µL of 1.5 M sucrose; 9 µL of 
gelatin was added 15 min later, and the mixture was dropped into a well (12 mm × 10 
mm) of a 8 well tissue culture chamber slide (Lab-Tec, Nunc) and allowed to dry. The 
cells were plated in the wells, and the localization of fluorescent proteins was observed 
under fluorescence microscope after replacement of the medium with DMEM without 
phenol red.  
 
Fluorescence immunocytochemistry 
To determine the localization of SS18 and SSX in transfected HEK293 cells, cells were 
seeded on glass culture slides (BD Falcon 8-well CultureSlide; BD Biosciences), and 
grown to 80% confluence. Cells were fixed in 1% formaldehyde for 10 min at room 
temperature, permeabilized, blocked with 1% bovine serum albumin (BSA) in PBS for 
30 min at room temperature, and then incubated with anti-SS18 antibody (SYT; C-19, 
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Santa Cruz Biotechnology, California, USA) or anti-SSX1 antibody (FL-188, Santa 
Cruz Biotechnology) overnight. Cells were washed and then incubated simultaneously 
with Alexa 594-conjugated secondary antibody (Invitrogen, Eugene, OR) for 1 h and 
Hoechst 33342 (1 mg/mL) (ICN Biomedicals, Aurora, OH) for nuclear staining. Images 
were acquired with SenSys0401E (Roper Scientific Germany, Ottobrunn, Germany), 
DMRA2 (Leica Microsystems, Wetzlar, Germany) and Leica Cytogenetic Workstation 
(CW4000; Leica Microsystems Imaging Ltd, Cambridge, UK). 
 
Western blotting analysis 
The protein samples (10 µg total proteins) were combined with gel loading buffer, 
heated to 95°C for 10 min, and then separated on 12% polyacrylamide gels. The 
proteins were subsequently transblotted onto PVDF membranes (Invitrogen) and 
blocked overnight at 4oC in 3% BSA/PBS. The immunoblots were incubated for 4 h at 
room temperature with anti-SS18 antibody (SYT; H-80, Santa Cruz Biotechnology) or 
anti-SSX1 antibody (FL-188, Santa Cruz Biotechnology). β-actin (Sigma, Saint Louis, 
USA) was used as a loading control. After washing with PBS/0.05% Tween-20, the 
filters were incubated with alkaline phosphatase-conjugated antibodies. The protein 
signal was visualized using FLA-3000 (Fujifilm). 
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Cell proliferation assay 
The plasmid pEGFP (control group) or pEGFP-tSSX2 (tSSX2 group) was transfected 
into SYO-1 cells cultured in 60 mm culture dish, and split into 4 plates of 60 mm cell 
culture dishes 48 h after transfection. The transfectants expressing the fluorescent 
proteins were observed and counted under a fluorescence microscope 4, 6 and 8 days 
after transfection. Ratio of the number of cells on days 6 and 8 to that of day 4 was 
calculated, and compared between tSSX2 and the control group.   
 
Colony formation assay 
SYO-1 cells were grown in 90 mm culture dish and were transfected with the plasmid 
pEGFP (control group) or pEGFP-tSSX2 (tSSX2 group), split into 10 plates of 60 mm 
culture dishes 48 h after transfection, selected with 400 µg/mL of G418 for two weeks, 
and stained with Giemsa stain solution after 4% formaldehyde fixation.   
 
Statistical analysis 
Comparison between the two groups in the cell proliferation assay was performed using 
t-test and p < 0.05 were considered statistically significant. StatView version 5.0 (SAS 
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Institute Inc., Cary, North Carolina) was used for statistical analysis.   
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Figure Legends 
Figure 1. Localization of synovial sarcoma-related proteins in synovial sarcoma 
SYO-1 cells.  
GFP fused proteins were observed using a fluorescence microscope. A, GFP-SS18; B, 
GFP-SSX1; C, GFP-SSX2; D, GFP-tSS18; E, GFP-tSSX1; F, GFP-tSSX2; G, 
GFP-SS18-SSX1; H, GFP-SS18-SSX2; I, GFP. Scale bars indicate 5 µm.  
 
Figure 2. Representative images showing the co-expression of GFP-tagged 
SS18-SSX2 and of DsRed-monomer-tagged truncated proteins in transfected 
SYO-1 cells. 
Fluorescent proteins were observed using a fluorescence microscope. A, co-expression 
of GFP-SS18-SSX2 (A1) and DsRed-monomer-tSS18 (A2); B, co-expression of 
GFP-SS18-SSX2 (B1) and DsRed-monomer-tSSX2 (B2); C, co-expression of 
GFP-SS18-SSX2 (C1) and DsRed-monomer empty vector (C2); D, co-transfection of 
GFP-SS18-SSX2 (D1) and DsRed-monomer-tSSX2 (D2) SYO-1 cell in which tSSX2 
was not expressed after co-transfection. Scale bars indicate 5 µm. 
 
Figure 3. Effect of increasing expression of tSSX on localization of SS18-SSX.  
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Plasmid pEGFP-SS18-SSX2 (2 µg) was co-transfected in HEK293 cells with 
pDsRedmonomer-tSSX2 (0, 2, 4, and 6 µg) (A), or DsRedmonomer-tSS18 (0, 2, 4, and 6 
µg) (B). The total DNA amount of transfection was complimented by pCMV-Tag2B 
empty plasmid without fluorescent protein (6, 4, 2, and 0 µg). The cells showing a 
speckled pattern or a diffuse pattern of SS18-SSX2 were counted in 30 fields of 
fluorescence microscope, and relative ratio of cells with speckled pattern was calculated 
(C). Scale bars indicate 10 µm. 
 
Figure 4. Exogenous expression of tSSX2 suppresses the proliferation of synovial 
sarcoma SYO-1 cells.  
SYO-1 cells were transfected with pEGFP-tSSX2 or pEGFP vector, split 48 h after 
transfection, and the cells expressing the GFP-tagged fusion proteins were counted on 
day 4, 6 and 8 after transfection. The cell proliferation ratio was normalized by dividing 
the number of cells expressing GFP-tagged proteins on days 6 and 8 by the number on 
day 4. Error bars indicate standard deviation, *p < 0.001, **p < 0.0001. 
 
Figure 5. Representative images showing changes in proliferation of SYO-1 cells 
expressing GFP-tSSX2 monitored for a period of 18 days.  
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SYO-1 cells were transfected with pEGFP-tSSX2 (A) or pEGFP vector (B), split 48 h 
after transfection, and the cells expressing GFP-tagged proteins were observed under 
fluorescence microscope on day 4, 6, 8, 10, and 18 after transfection. 1, day 4; 2, day 6; 
3, day 8; 4, day 10; 5, day18. Scale bars indicate 20 µm. 
 
Figure 6. A. Exogenous expression of tSSX suppresses the colony formation in 
SYO-1 cells.  
SYO-1 cells cultured in 90 mm dishes were transfected with pEGFP empty vector (A1) 
or pEGFP-tSSX2 (A2), split into 10 plates of 60 mm dishes 48 h after transfection and 
selected with G418 for three weeks. The cells were fixed in 4% formaldehyde and 
stained with Giemsastain solution. B, YaFuSS cells were transfected with pEGFP empty 
vector (B1) or pEGFP-tSSX2 (B2), and assessed for colony formation activity. The 
colonies were counted and the average number of colonies formed is shown as bar 
graphs for SYO-1 (A3) and YaFuSS (B3). Error bars indicate standard deviation, * p < 
0.01. 
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Supplementary Figure 1. Localization of synovial sarcoma-related proteins by 
fluorescence immunocytochemistry.  
HEK293 cells were transfected with pCMV-Tag2B-SS18, pCMV-Tag2B-SSX2, and 
pCMV-Tag2B-SS18-SSX2, and analyzed by fluorescence immunocytochemistry with 
anti-SS18 and anti-SSX antibodies. The transfected cells with SS18 and SS18-SSX2 
were reacted with anti-SS18 antibody (upper and middle, respectively), and the SSX2 
transfectant was reacted with anti-SSX antibody (lower). Left, antibody reaction using 
Alexa 594-conjugated secondary antibody; middle, Hoechst33342 staining; right, 
merged image. Scale bars indicate 5 µm.  
 
Supplementary Figure 2. Localization of synovial sarcoma-related fusion proteins 
in HEK293 cells.  
Cells expressing GFP-tagged proteins were observed under a fluorescence microscope. 
A, GFP-SS18; B, GFP-SSX1; C, GFP-SSX2; D, GFP-SS18-SSX1; E, 
GFP-SS18-SSX2; F, GFP. Scale bars indicate 5 µm.   
 
Supplementary Figure 3. Confirmation of protein expression from plasmid 
constructs by Western blotting.  
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A, HEK293 cells were transfected with pEGFP (lane 1), pEGFP-SS18 (lane 2, about 79 
kDa), pEGFP-SS18-SSX1 (lane 3, about 83 kDa), pEGFP-SS18-SSX2 (lane 4, about 83 
kDa), pEGFP-tSS18 (lane 5, about 77 kDa), pDsRedmonomer-tSS18 (lane 6, about 81 
kDa), and pDsRedmonomer (lane 7), and the cell extracts were detected by western 
blotting with anti-SS18 antibody. B, HEK293 cells were transfected with pEGFP (lane 
1), pEGFP-SSX1 (lane 2, about 51 kDa), pEGFP-tSSX1 (lane 3, about 38 kDa), 
pDsRedmonomer-tSSX1 (lane 4, about 42 kDa), pDsRedmonomer (lane 5), pEGFP 
(lane 6), pEGFP-SSX2 (lane 7, about 51 kDa), pEGFP-tSSX2 (lane 8, about 38 kDa), 
pDsRedmonomer-tSSX2 (lane 9, about 42 kDa), and pDsRedmonomer (lane 10), and 
the cell extracts were detected by western blotting with anti-SSX antibody. 
 
Supplementary Figure 4. Changes in the localization of SS18-SSX1 when 
co-expressed with DsRedmonomer tagged truncated SS18 or SSX1 proteins in 
SYO-1 cells.  
A, co-expression of GFP-SS18-SSX1 (A1) and DsRedmonomer-tSS18 (A2); B, 
co-expression of GFP-SS18-SSX1 (B1) and DsRedmonomer-tSSX1 (B2). Scale bars 
indicate 5 µm 
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Supplementary Figure 5. Changes in the localization of SS18-SSX2 when 
co-expressed with DsRedmonomer-tSS18 or -tSSX2 proteins in HEK293 cells.  
pEGFP-SS18-SSX2 (2 µg) was transfected in HEK293 cells with 6 µg of 
pDsRedmonomer (left), pDsRedmonomer-tSSX2 (middle), and pDsRedmonomer-tSS18 
(right). Upper, GFP protein; middle, DsRedmonomer protein; lower, merged image. 
White arrow shows a cell with speckled pattern of SS18-SSX2 in which 
DsRedmonomer-tSSX2 was not expressed. Scale bars indicate 10 µm  
 
Supplementary Figure 6. Changes in the localization of SS18-SSX when 
co-expressed with DsRedmonomer tagged truncated SS18, SSX1 or SSX2 proteins 
in HEK293 cells. 
A, co-expression of GFP-SS18-SSX1 (A1) and DsRedmonomer-tSS18 (A2); B, 
co-expression of GFP-SS18-SSX2 (B1) and DsRedmonomer-tSS18 (B2): C, 
co-expression of GFP-SS18-SSX1 (C1) and DsRedmonomer-tSSX1 (C2); D, 
co-expression of GFP-SS18-SSX2 (D1) and DsRedmonomer-tSSX2 (D2). Scale bars 
indicate 5 µm. 
 
Supplementary Figure 7. Effect of DsRedmonomer-tSSX2 on GFP-SS18-SSX2 
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expression in transfected HEK293 cells. 
Plasmid pEGFP-SS18-SSX2 (2 µg) was transfected in HEK293 cells with 6 µg of 
pDsRedmonomer (lane 1), pDsRedmonomer-tSSX2 (lane 2), and 
pDsRedmonomer-tSS18 (lane 3), and the total extracts (10 µg) were analyzed by 
western blotting analysis with anti-SS18 antibody (upper), anti-FLAG antibody 
(middle), and anti-β actin antibody (lower). The pDsRedmonomer vector contains 
FLAG-tag.  
 
